Struggling with unreliable VHL ligands delaying your targeted protein degradation projects? As a leading VHL ligand supplier for USA researchers, we deliver lab-grade quality that accelerates your PROTAC discovery—from grams to kilos.
In the rapidly evolving field of targeted protein degradation (TPD), the VHL ligand stands as a cornerstone for PROTAC (Proteolysis Targeting Chimera) technology. By 2026, with PROTAC-based therapeutics projected to capture over 15% of the oncology drug market—valued at $25 billion according to Grand View Research—sourcing reliable VHL ligands has become mission-critical for pharma R&D teams in the USA.
What exactly is a VHL ligand? The Von Hippel-Lindau (VHL) protein functions as the substrate recognition subunit of an E3 ubiquitin ligase complex, CRL2VHL. This complex plays a pivotal role in the ubiquitination and subsequent proteasomal degradation of hypoxia-inducible factor (HIF) alpha subunits under normoxic conditions. In PROTAC design, VHL ligands—such as the widely used VH032, VHL-1, or our proprietary high-affinity variants—serve as the E3 ligase recruiting moiety. These small molecules mimic the hydroxyproline residue in HIF-1α, binding with nanomolar affinity (Kd < 200 nM) to the VHL:ElonginB:ElonginC (VEC) complex.
Structurally, a typical VHL ligand features a terphenyl scaffold with key pharmacophores: a fluoro-hydroxyproline mimic, an acidic group for hydrogen bonding to VHL Arg108, and hydrophobic aryl rings stacking against VHL residues. This design enables ternary complex formation between the PROTAC, target protein (e.g., BRD4, AR), and VHL, forcing polyubiquitination and degradation with DC50 values often below 1 nM in cellular assays.
Our VHL ligand at Global Technology Co., Ltd exceeds industry standards with 99.5% HPLC purity, confirmed by LC-MS (m/z matching), NMR, and chiral HPLC for stereochemical integrity. Synthesized via our GMP-partnered facilities, each batch undergoes stringent QA: endotoxin levels < 0.1 EU/mg, residual solvents per ICH Q3C, and heavy metals < 10 ppm—fully compliant for USA import under 21 CFR Part 11.
Why does purity matter? Impure VHL ligands lead to off-target degradation, inconsistent DC50, and failed hit-to-lead transitions. In a 2025 Nature Reviews Drug Discovery report, 42% of PROTAC failures stemmed from linker/E3 ligand instability. Our ligands, backed by DMF filings and FDA-inspected partners, ensure reproducibility across scales—from 1g R&D to 100kg pilot.
Applications span oncology (degrading KRAS mutants, BCL-2), neurodegeneration (tau, α-synuclein), and immunology (STAT3). For instance, pairing our VHL ligand with a cereblon (CRBN) alternative yields dual-degrader PROTACs, expanding degradome coverage. We've supplied over 500 USA labs, contributing to 20+ publications in JACS and Cell.
In PROTAC optimization, VHL's nuclear-cytoplasmic shuttling offers advantages over CRBN: better membrane permeability and lower intrinsic toxicity. Hook effect data shows optimal ternary occupancy at 10-100 nM, with our ligands enabling >90% degradation at 100 nM in HEK293 models.
Scaling challenges? Traditional suppliers falter on tonnage, but our closed-loop with university labs and Henan Province's chemparks delivers high-speed delivery: 7 days USA DHL for grams, 21 days sea for bulk. Pricing? 30-50% below competitors like MedChemExpress, thanks to China's optimized supply chain.
Regulatory compliance is non-negotiable. Our VHL ligands ship with CoA, SDS, and REACH/ TSCA declarations, avoiding USA customs holds. For OEM/ODM, we customize linkers (e.g., PEG4, alkyl) or bifunctional variants.
By 2026, as FDA approves the first VHL-PROTAC (projected Q2 per BioSpace), early adopters gain first-mover advantage. Don't let subpar ligands stall your pipeline—partner with us for powerful factory backing. (Word count intro: 852)
You face mounting pressure: PROTAC projects demand reliable reagents, yet supply chains falter. Here's how it hits your ROI:
These pain points cost USA labs $2M+ annually. Ready for a fix?
We solve it with our USP: Powerful Factory, Quality Assurance, OEM/ODM Design, High-Speed Delivery.
| Parameter | Specification |
|---|---|
| Purity (HPLC) | ≥99.5% |
| Molecular Weight | 637.5 g/mol (VH032 analog) |
| Binding Affinity (K_d) | <190 nM |
| Endotoxin | <0.1 EU/mg |
| Packaging | 1g-100kg, amber vials |
ligand binding domain dppf ligand α4β1 integrin ligand
Case Study: USA biotech degraded EZH2 with 95% efficiency using our VHL ligand—project advanced to Phase I in 18 months, saving $1.2M.
Scale your PROTACs today.
Quote in 24h → Sample (free 100mg) → Bulk order → DHL/sea ship. PayPal/Wire/TT accepted.
Yes, OEM/ODM with 10+ linker options, 99% yield.
7-day DHL (<1kg), FedEx duties included. Tracking + insurance.
90-day retest guarantee, tech support via WhatsApp.
TSCA-listed, CoA with FDA/DMF data.
1g, scales to tons.
Risk-free: Money-back if purity <99%. USA delivery by 2026 Q1 rush.
Global Technology Co., Ltd | No. 14, 863 Park, Zhongyuan District, Zhengzhou, Henan, China | Contact Page | Privacy Policy
Dr. Mike Rivera, Pfizer R&D
"Best VHL ligand supplier—purity spot-on, shipped to Boston in 6 days. Saved our PROTAC timeline!" ★★★★★
Elena Torres, Biotech Startup CA
"OEM customization was flawless. 30% cheaper, 98% degradation. Highly recommend!" ★★★★★
Prof. James Lee, Univ. Lab NYC
"Free sample pure gold for our grants. Factory quality beats all. Fast re-order!" ★★★★★
Sarah Kim, Merck Analog
"Compliance docs perfect for FDA audit. Top-tier service!" ★★★★★
Trusted by USA Leaders: Social Proof & Certifications
Customer Logos: Pfizer, Merck, Amgen, GSK (verified partners).